BioLineRx (BLRX) Change in Accured Expenses (2018 - 2025)

BioLineRx's Change in Accured Expenses history runs 6 years deep, the most recent figure standing at -$568000.0 for Q3 2025.

• In Q3 2025, Change in Accured Expenses rose 3.07% year-over-year to -$568000.0; the TTM figure through Sep 2025 stood at -$3.6 million (up 39.79% YoY), while the FY2013 annual figure was -$3.9 million, changed N/A from the prior year.
• Change in Accured Expenses was -$568000.0 for Q3 2025 at BioLineRx, down from $25000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $180000.0 in Q3 2021 to a low of -$3.5 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged -$1.1 million across 3 years, with a median of -$568000.0 in 2025.
• Biggest YoY gain for Change in Accured Expenses was 113.34% in 2021; the steepest drop was 243.38% in 2021.
• A 3-year view of Change in Accured Expenses shows it stood at $180000.0 in 2021, then sank by 425.56% to -$586000.0 in 2024, then advanced by 3.07% to -$568000.0 in 2025.
• The last three Change in Accured Expenses figures came in at -$568000.0 (Q3 2025), $25000.0 (Q2 2025), and -$2.5 million (Q1 2025), per Business Quant data.